{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:48:44Z","timestamp":1773964124871,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.schres.2014.05.040","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T01:10:25Z","timestamp":1404263425000},"page":"112-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: A randomized, double-blind, active parallel-controlled, multicenter clinical trial"],"prefix":"10.1016","volume":"157","author":[{"given":"Huafang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niufan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.schres.2014.05.040_bb0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0269881110376685","article-title":"Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis","volume":"25","author":"Chung","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"Suppl. 7","key":"10.1016\/j.schres.2014.05.040_bb0010","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.05.040_bb0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.schres.2014.05.040_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4088\/JCP.v68n0104","article-title":"Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial","volume":"68","author":"Chan","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.05.040_bb0025","article-title":"Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?","author":"Charpeaud","year":"2014","journal-title":"Enc\u00e9phale"},{"issue":"2","key":"10.1016\/j.schres.2014.05.040_bb0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","article-title":"Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine","volume":"189","author":"Chrzanowski","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"10.1016\/j.schres.2014.05.040_bb0040","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1176\/ajp.148.12.1697","article-title":"New methods in cross-cultural psychiatry: psychiatric illness in Taiwan and the United States","volume":"148","author":"Compton","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2014.05.040_bb0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"16","key":"10.1016\/j.schres.2014.05.040_bb0030","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.schres.2014.05.040_bb0050","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.05.040_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","article-title":"Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile","volume":"18","author":"Hirose","year":"2004","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2014.05.040_bb0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-3565(25)12799-7","article-title":"Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland","volume":"277","author":"Inoue","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.schres.2014.05.040_bb0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.05.040_bb0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2014.05.040_bb0075","first-page":"CD006569","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","volume":"1","author":"Khanna","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.schres.2014.05.040_bb0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)10600-9","article-title":"7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.schres.2014.05.040_bb0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0006-3223(97)00030-9","article-title":"Antipsychotic properties of the partial dopamine agonist (\u2212)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia","volume":"43","author":"Lahti","year":"1998","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.05.040_bb0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.schres.2014.05.040_bb0095","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20mg\/day for the treatment of patients with acute exacerbations of schizophrenia","volume":"41","author":"McEvoy","year":"2007","journal-title":"J. Psychiatr. Res."},{"issue":"Suppl. 18","key":"10.1016\/j.schres.2014.05.040_bb0100","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2014.05.040_bb0105","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2014.05.040_bb0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.05.040_bb0115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4088\/JCP.5055ah5cj","article-title":"A roadmap to key pharmacologic principles in using antipsychotics: application in clinical practice","volume":"70","author":"Preskorn","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.05.040_bb0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145706006523","article-title":"Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole","volume":"10","author":"Raja","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2014.05.040_bb0125","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/schbul\/sbr006","article-title":"Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis","volume":"38","author":"Tadokoro","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2014.05.040_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-200302000-00010","article-title":"Psychotropic drugs, cardiac arrhythmia, and sudden death","volume":"23","author":"Witchel","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2014.05.040_bb0135","first-page":"69","article-title":"Epidemiological survey on mental disorders in 7 areas in China","volume":"31","author":"Zhang","year":"1998","journal-title":"Chin. J. Psychiatry"}],"updated-by":[{"DOI":"10.1016\/j.schres.2014.07.035","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000}}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414003053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414003053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:38:10Z","timestamp":1746290290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414003053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":27,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0920996414003053"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.05.040","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.schres.2014.07.035","asserted-by":"object"}]},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: A randomized, double-blind, active parallel-controlled, multicenter clinical trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.05.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}